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Introduction
Although successful antiretroviral therapy (ART) does not cure HIV infection, it effectively inhibits 
viral replication, the progressive loss of  CD4+ cells, and the development of  AIDS in most infected 
individuals. There is still some debate about whether HIV persists in treated individuals because of  low 
levels of  ongoing replication. For example, it has been suggested (1) that there is ongoing replication in 
treated individuals; however, this paper has been challenged (2, 3). Overall, the weight of  the evidence 
strongly suggests that successful ART completely blocks HIV replication (4–7). The viral reservoir is 
maintained because viral genomes persist as integrated proviruses in long-lived infected cells. In indi-
viduals on long-term ART, most of  the integrated proviruses (95%–98%) are defective (8, 9). The intact, 
infectious proviruses that can rekindle infection in an ART-treated individual are collectively referred 
to as the HIV reservoir. Despite representing only a small fraction of  the total viral DNA load (8, 10), 
intact proviruses are sufficiently numerous to prevent eradication of  the infection in nearly every patient 
tested to date. The first successful cure involved whole-body irradiation, 2 bone marrow transplants, 
and transplantation of  bone marrow from a homozygous delta32 CCR5 donor naturally resistant to 
HIV infection (11). More recently, a second individual appears to have been cured through an alloge-
neic stem cell transplant from a delta32 CCR5 homozygote donor (12). However, other HIV-infected 
patients who have undergone allogeneic stem cell transplantation have died or suffered a relapse of  
their HIV infection, suggesting that the reservoir is large enough that eliminating it completely will be 
very difficult (13–16). It also appears, based in part on studies done with SIV-infected macaques and the 
earliest treated HIV-infected humans, that the reservoir is established rapidly (within the first few days 
following the initial infection) (17–19), and that, after a fairly rapid initial decline following the initia-
tion of  long-term ART, the size of  the reservoir diminishes only very slowly, if  at all, over the lifetime 
of  infected individuals (20, 21).
In HIV-infected individuals on long-term antiretroviral therapy (ART), more than 40% of the 
infected cells are in clones. Although most HIV proviruses present in individuals on long-term ART 
are defective, including those in clonally expanded cells, there is increasing evidence that clones 
carrying replication-competent proviruses are common in patients on long-term ART and form part 
of the HIV reservoir that makes it impossible to cure HIV infection with current ART alone. Given the 
importance of clonal expansion in HIV persistence, we determined how soon after HIV acquisition 
infected clones can grow large enough to be detected (clones larger than ca. 1 × 105 cells). We studied 
12 individuals sampled in early HIV infection (Fiebig stage III–V/VI) and 5 who were chronically 
infected. The recently infected individuals were started on ART at or near the time of diagnosis. We 
isolated more than 6,500 independent integration sites from peripheral blood mononuclear cells 
before ART was initiated and after 0.5–18 years of suppressive ART. Some infected clones could be 
detected approximately 4 weeks after HIV infection and some of these clones persisted for years. 
The results help to explain how the reservoir is established early and persists for years.
This last result would appear to be at odds with the fact that, in people who are not on ART, most 
HIV- infected cells live only about a day, due to effects of  the viral infection, recognition of  infected cells 
by the host’s immune system, or both (22, 23). However, a fraction of  infected cells (including some that 
carry infectious proviruses) survive long term. We suggest that most of  the cells that survive enter a poorly 
defined state of  latency and make little or no viral RNA or protein, allowing them to survive long term 
(19); however, it has also been suggested that some of  cells that carry infectious proviruses are intrinsically 
resistant to killing by CD8+ cells (24). It is generally thought that a significant fraction of  the cells that con-
stitute the reservoir are CD4+ T cells, particularly central memory T cells. Because it is the long-lived cells 
that carry infectious proviruses that constitute the reservoir, it is important to understand how these cells 
are generated and maintained.
We and others have shown that, in infected individuals on long-term ART, a significant fraction of  the 
HIV-infected cells have expanded into clones that were detected because the integration sites of  their pro-
viruses are identical (25, 26). Although it has been suggested that only cells that carry defective proviruses 
can clonally expand (27), Simonetti et al. (28) showed that a large clone of  cells carrying an infectious pro-
virus (called AMBI-1 and estimated to comprise ca. 1 × 107 cells) was present in one patient, and that virus 
produced by this clone was present at readily detectable levels in his blood (at ca. 150 HIV RNA copies 
per mL) at multiple time points. Production of  low levels of  virus from large clones of  cells infected with 
intact infectious proviruses could account for at least some of  the reports that there are patients who have 
low levels of  virus in the blood that are not affected by treatment intensification (4, 29, 30). Additional data 
showing that there are intact proviruses in clonally expanded cells was recently reported by Einkauf  et al. 
(31). These data show that clonally expanded cells can be an important part of  the reservoir; however, that 
raises the question of  how such clones are able to survive and expand. Further analysis showed that only a 
small fraction (2%–3%) of  the cells in the AMBI-1 clone were making viral RNA at any one time, implying 
that only a small fraction of  the cells in the clone could have been producing viral protein at any one time 
(28). In samples taken from other HIV-infected individuals, a similarly small fraction of  the cells in clones 
that carry either obviously defective or apparently intact (and potentially infectious) proviruses express 
viral RNA (19). These observations suggest that infected clones are able to survive and expand because the 
majority of  cells do not express viral RNA or protein. Because the half-life of  productively infected cells is 
only about 1 day (23), the presence of  detectable levels of  AMBI-1 virus in the blood of  this patient for at 
least 3 years implies a mechanism by which small numbers of  virus-producing cells were constantly being 
generated from their much more numerous clonal siblings whose proviruses were transcriptionally silent.
Because AMBI-1 is a single clone, found in a single patient, it is not yet clear how many other patients 
also have similar large clones that carry infectious proviruses. However, several groups (3, 19, 32, 33) used 
viral outgrowth assays to show that patients on long-term ART commonly contain multiple cells that can 
produce identical infectious viruses. Although it has not been conclusively demonstrated that the cells that 
produced the identical viruses clonally expanded from a single infected cell, that is the likely explanation. 
Thus, we favor the idea that, not only are there infected cells that have clonally expanded in patients, but 
also that clonally expanded cells make up a significant part (perhaps all) of  the reservoir that makes it 
impossible to cure HIV infection with current ART alone. Clonal expansion of  infected cells would explain 
how the reservoir remains relatively stable for long periods of  time. If  some of  the cells in a clone that carry 
an infectious provirus die, the dead cells could be replaced by the proliferation of  other cells in the clone. In 
addition, if  some clones were to diminish in size during long-term treatment, it is also possible that other 
clones could increase in size, preserving an approximately constant steady-state level of  infectious proviral 
DNA. It is also likely that the same processes responsible for T cell maintenance and expansion account for 
most of  the clonal expansion and persistence of  the infected cells.
If  clonally expanded cells make up a significant fraction of  the reservoir, then we would expect that 
clones of  infected cells would begin to arise at the time the reservoir is first formed. The frequency at 
which long-lived infected cells are generated in vivo is unknown, but, given the large number of  cells that 
are infected and die each day (23), the fraction is likely to be quite low, and, at least at early times after the 
initial infection, the abundance of  the long-lived cells will increase relative to the short-lived productively 
infected cells. To test this idea, we obtained peripheral blood mononuclear cells (PBMCs) from individuals 
who had been infected with HIV for varying periods of  time. In most cases, infected individuals do not 
know the exact date when they were infected. It is, however, possible to estimate the time that has elapsed 
after the initial infection using Fiebig staging, which depends on the fact that it is possible to detect viral 
RNA and proteins in the blood of  an infected individual before there is a detectable immune response, and 
that, in most cases, the humoral immune response to several of  the viral proteins occurs in a particular 
temporal order (34). There is a brief  eclipse period before viral RNA can first be detected in the blood 
(perhaps a week), and then the first 4 Fiebig stages arise over a period of  about a month. Thus, the Fiebig 
III–IV stages are estimated to be approximately 3 to 4 weeks after the initial infection. Fiebig V lasts from 
about 4 weeks to about 3 months.
In the present study, we show that clones are formed within the first few weeks after the initial infec-
tion, that clonal expansion of  infected cells can be detected as early as the end of  Fiebig IV/beginning of  
Fiebig V, and that clones created early in infection can persist for at least 3.7 years of  suppressive ART.
Results
Participants and sampling. We analyzed samples from 3 groups of  HIV-infected participants who were 
diagnosed at various stages of  infection (Table 1). The first group (group 1) comprised 7 individuals from 
the UNC-Duke AHI Cohort/CHAVI project and one from the University of  Pittsburgh Acute Infection 
protocol. Two of  the participants were determined to be in Fiebig III, one in Fiebig IV, one on the cusp 
between Fiebig IV and V, and 3 in Fiebig V at the time of  first sampling. The second group (group 2) 
included 5 participants enrolled in AVBIO1, AVBIO2, and IDFU studies of  antiretroviral therapy at 
NIH who initiated ART somewhat later after the initial infection. Four of  these donors were diagnosed 
in Fiebig V, and one was diagnosed in Fiebig VI. The third group of  donors (group 3) was also from 
the NIH and included 5 individuals who had been infected for long periods of  time (up to 14.8 years) 
before initiating ART. In terms of  determining when clones of  infected cells can grow large enough 
for us to detect them, the first 2 groups are the most important; the third group served as a control that 
allowed us to estimate how much more difficult it was to identify clones when there is a large back-
ground of  recently infected cells that are present in untreated donors. The donors in the first 2 groups 
were separated based on the time from infection to when ART was initiated, when the initial samples 
were obtained, and approximately how long the donors were on ART before the last on-ART sample 
was obtained. In all 3 groups, plasma and PBMC samples were collected and analyzed to determine 
Table 1. Study participant characteristics
Group Patient  
identifier
Plasma HIV RNA copies/mL  
at first sampling time point
Fiebig stage or years infected  
at first sample (pre-ART)
Duration of suppression on ART 
at final on ART sample (years)
Plasma HIV RNA at final on 
ART sample (copies/mL)
1
CH 83-1 750,000 III 1.5 <40
CH 84-4 155,000 III 3.2 <40
PIT 001 2,137,000 IV 0.9 <40
CH 62-1 387,000 IV/V 3.7 <40
CH 68-5 134,000 V 3.6 <50
CH 91-4 589,000 V 2.9 <50
CH 98-6 254,000 V 2.8 <40
2
IDFU-192 31,000 V 11.4 <40
IDFU-194 151,000 V 3.6 <50
AVBIO2-14 351,000 V/VI 17.8 <40
AVBIO2-23 143,000 V/VI 16.6 <50
AVBIO2-04 201,000 VI 17.7 <40
3
AVBIO2-21A 382,000 14.8 7.2 828
AVBIO2-08B 33,600 Unknown 16.3 <40
AVBIO2-18C 35,400  6.5 12.2 <50
AVBIO1-102 14,000  4.9 1.76 <50
AVBIO2-03B 83,500 Unknown 19.7 <40
AThis is the same donor identified as patient 3 in Maldarelli et al. (25). BThese 2 donors were diagnosed by a positive HIV ELISA/Western blot 1–3 months 
prior to sampling with CD4+ cell counts <200 cells/μL, and other symptoms consistent with having a longstanding infection. CThis is the same donor 
identified as patient 4 in Maldarelli et al. (25). 
the levels of  cell-free HIV RNA and cell-associated HIV DNA both before ART was initiated and after 
they had been on ART for 2.7–17.8 years. We obtained additional longitudinal samples on ART from 
some of  the donors in group 1.
With one exception, the pre-ART PBMC samples used for integration site analysis, single-genome 
sequencing (SGS), and viral DNA loads were taken from the group 1 and 2 donors at the same time as 
Fiebig staging. In the one case, identified as Fiebig IV/V, the sample used for SGS and integration site 
analysis was taken 2 weeks after an initial sampling identified the individual as being Fiebig IV; thus, this 
individual could have progressed to early Fiebig V by the time the second sample was taken. In all group 1 
participants viremia was fully suppressed on ART, and, with one exception, all were fully suppressed (<50 
copies HIV RNA/mL) at the intermediate times as well. On-ART samples were obtained from the group 1 
donors at various times from 0.9 to 3.7 years.
Plasma and PBMC samples were obtained from the donors in group 2 at the time of  Fiebig staging 
(with 2 exceptions, denoted as “V/VI” in Table 1, who were sampled about 2 months and 1 month follow-
ing staging) and during ART. On average, participants in group 2 had been on ART for a longer period of  
time than those in group 1 (median 16.6 years at the time of  sampling). Group 3 included 5 individuals 
who had been infected for long periods (up to 14.8 years) before initiating ART. We analyzed samples taken 
before these individuals initiated ART and after they had been on ART for up to 16.3 years.
The donors in group 1 were, with one exception, well suppressed. Donor CH 083-1 had a brief  treat-
ment interruption, during which viremia rebounded. In group 2, IDFU-192 had a treatment interruption, 
but had been fully suppressed for more than 9 years when the on-ART sample was taken. IDFU-194 had 
one very small blip early in the treatment period. AVBIO2-04 was poorly controlled early in the course of  
treatment but was well suppressed for more than 10 years. AVBIO2-14 and AVBIO2-23 had low-level blips 
early in the course of  their treatment but were well suppressed for more than 10 years, and more than 8 
years, respectively. In group 3, AVBIO2-08, AVBIO1-18, and AVBIO2-03 each had one minor blip before 
the on-ART samples were taken. AVBIO1-102 had one blip early in therapy but after that was suppressed 
below the limit of  detection (LOD) until the on-ART sample was taken. However, all of  the donors were 
well suppressed at the times on-ART samples were obtained, except AVBIO2-21, who had HIV RNA of  
828 copies/mL when the last on-ART sample was taken.
Levels of  viremia and infected cells on ART. Plasma HIV RNA and PBMC HIV DNA levels were measured 
in the samples from all donors (Tables 1, 2, and 3). As expected, all donors exhibited a large reduction in the 
amount of viral RNA (Table 1) and DNA (Tables 2, 3, and 4) on ART. Viral DNA values in the samples taken 
at the last time point on ART, compared to the pretherapy samples, are summarized in Table 5 and Figure 1A. 
The decline in viral DNA was greater in the donors treated in early infection than in those treated at later stages 
(Figure 1A). The total decline of the viral DNA in PBMCs averaged about 360-fold for the Fiebig III donors, 
about 50- to 70-fold for the Fiebig IV–V donors, and about 11-fold for the chronic donors (Figure 1A and Table 
5). However, there were considerable differences in the plasma viral RNA and cellular DNA levels among the 
individual donors (both before and after ART) with no obvious correlation with Fiebig stage at which the indi-
viduals were diagnosed or initiated ART. Nonetheless, in all cases, the decrease in the viral DNA in the group 
1 and 2 donors who initiated ART soon after they were infected was significantly greater (paired log ratio test P 
< 0.001) when compared with the decrease in viral DNA load in the donors who initiated ART during chronic 
infection (group 3, see Table 5), as has been reported previously (17, 35, 36).
No evidence of  HIV replication in the donors on ART. The decline in plasma viral RNA levels on ART to 
values below the LOD (with one exception) is consistent with an absence of  significant viral replication 
after these individuals initiated ART (4, 6, 7). However, it has been claimed that the level of  viral replication 
in sanctuary sites during ART, such as the lymph nodes, is sufficient to lead to detectable evolution in the 
sequences of  the proviruses in PBMCs (1). This proposal is controversial and has been challenged by us and 
others (2, 3). Because we were specifically interested in determining the contribution of  clonal expansion 
of  infected cells to the generation and maintenance of  the reservoir, we used SGS to look for evidence of  
sequence evolution (which would imply ongoing virus replication) in the proviral DNA in 5 of  the indi-
viduals in group 1. The advantage of  doing evolutionary analysis on proviral DNA from individuals who 
initiated ART shortly after they were infected is that, if  they were infected by a single virion, as is usually 
the case, their HIV genomes should have low sequence diversity at the time ART is initiated (4, 37). Thus, if  
there was enough viral replication to allow the virus to evolve, it should be relatively easy to detect changes 
in the sequences of  the HIV proviruses in these individuals over time. As shown in Figure 2, the populations 
of  proviruses present in all of  the Fiebig III–V donors we tested were nearly homogeneous, as expected, 
providing no evidence of  evolution in the sequences of  the HIV proviruses in the 5 individuals in group 1 
who were on ART continuously for periods of  2.8 to 3.7 years. This result implies that, if  there was any viral 
replication in these individuals while they were on ART, it must have either been at a very low level or it 
occurred only in sites that did not communicate with the blood.
Clonal expansion of  HIV-infected cells. We used the methods described in Maldarelli et al. (25) to determine 
and analyze the sites of proviral DNA integration in PBMC samples taken from the donors both before ART 
and on ART. As expected, there was a correlation between the viral DNA copy number and the number of  
integration sites we recovered (Tables 2 and 3 and Supplemental Figure 1; R2 = 0.8; supplemental material 
available online with this article; https://doi.org/10.1172/jci.insight.128432DS1). We were particularly inter-
ested in determining how soon after infection clonal expansion of HIV-infected cells could be detected in sam-
ples taken before ART was initiated. In the integration site assay, clonal expansion is measured by the number 
of different DNA breakpoints associated with specific integration sites (38). However, as explained more fully 
in the Discussion, there are important differences in the way we interpreted the breakpoint data from samples 
obtained from pre-ART and on-ART donors. In an untreated individual, integrated viral DNA can be either in 
recently infected cells that are producing viral proteins and are destined to die within a few days, or in cells that 
carry highly defective or latent proviruses, most of which do not express viral proteins (22). Some of the latter 
cells can survive and divide for many years (35, 39). Therefore, in samples taken from untreated individuals, 
much of the viral DNA is in newly infected cells, which create a background that makes it more difficult to 
use integration site analysis to detect clonally expanded cells. Because HIV preferentially infects dividing cells, 
there are likely to be infected cells present that have replicated their DNA (including integrated viral DNA) but 
have not yet divided and are destined to die soon. In an individual who has been on therapy for years, most pro-
virus-containing cells that are dividing are not making viral RNA (19). The dividing cells that are not making 
viral RNA are not about to die and are almost certainly members of a clone. As a consequence, if  we recover 
the same end of a provirus from an on-ART sample with 2 (or more) different-sized host DNA fragments (2 or 
more breakpoints), we can safely conclude that the integration site is in a clone. In contrast, in samples taken 
from untreated donors, although integration sites with 2 breakpoints may have come from a clone, we cannot 
Table 2. Pre-ART cell-associated HIV DNA, integration sites, and clones in PBMCs from the donors put on ART shortly after infection 
(groups 1 and 2)








FIII (CH 83-1) 50,000 3 1,409 1 0
FIII (CH 84-4) 1,700 1.5 176 2 0
FIV PIT-001 14,000 1.5 149 1 0
Average per 106 cells 22,000 290 0.67 0
SD FIII–IV 25,000 210 0.51 0
1b
FIV/V (CH 62-1) 18,000 4.5 709 14 9
FV (CH 68-5) 5,600 1.5 366 1 0
FV (CH 91-4) 4,800 4.5 416 3 1
FV (CH 98-6) 1,900 3 179 2 2
Average per 106 cells 7,600 120 1.5 0.87
SD FIV/V–V 7,100 42 1.2 0.9
2
FV (IDFU-192) 17,000 1.5 409 3 0
FV (JRI) 1,500 3 193 1 1
FV/VI (AVBIO2-14) 4,300 1.5 144 0 0
FV/VI (AVBIO2-23) 21,000 1.5 405 3 0
FVI (AVBIO2-07) 2,100 1.5 48 0 0
Average per 106 cells 9,200 130 0.89 0.11
SD 9,100 120 0.94 0.15
APer million cells. F, Fiebig; PID, patient identifier; ISA, integration site analysis.
safely conclude that we have identified a clone unless we isolate the same integration site with 3 or more break-
points, or from at least 2 independently analyzed samples taken from the same individual. Thus, the integration 
site data, and the clone counts, will not be strictly comparable in samples taken from pre-ART and on-ART 
donors, and for that reason, the pre-ART and the on-ART data for groups 1 and 2 are presented in different 
tables. Because some or all of  the integration sites with 2 breakpoints obtained from samples from untreated 
donors may not derive from clones of infected cells, such data are presented in Tables 2–5 as “integration sites 
with more than one breakpoint” and in Figure 1C by green circles.
For comparison to the early infection samples, we analyzed the integration sites from 5 individuals 
who had been infected for long periods of  time (up to 14.8 years) before initiating ART (group 3, Table 4). 
We obtained integration sites from samples taken before these individuals initiated ART and after they had 
been on ART for up to 16.3 years.
Table 2 shows the pre-ART integration site data from the donors in groups 1 and 2. We were able to 
confirm the presence of  infected cells that had clonally expanded in some, but not all, of  the pre-ART 
samples from group 1. Clones were identified in 3 of  the 4 pre-ART samples from the Fiebig IV/V and V 
donors. There were a number of  integration sites with 2 breakpoints in samples from the 3 Fiebig III and 
IV donors; however, we did not detect any confirmed clones in these samples. Although the number of  
clones we identified in the group 1 pre-ART samples was small, there was a statistically significant differ-
ence (P = 0.0002) in the frequency of  confirmed clones between the Fiebig III–IV and IV/V–VI donors; 
the frequency of  sites with 1 or more breakpoints was not significantly different among the groups (Table 5 
and Figure 1C; compare green circles to purple circles). The data are consistent with there being an inter-
val of  approximately 4 weeks between the initial infection and the most rapidly expanding clones reaching 
a size that we can unambiguously detect.
In addition to 1 pre-ART and 1 on-ART PBMC sample, we obtained 1 or 2 intermediate on-ART PBMC 
samples from all but one of  the infected individuals in group 1 (Table 2, Supplemental Table 1A, and Sup-
plemental Table 2). The intermediate and final on-ART data were combined for all subsequent analyses. As 
Table 3. On-ART cell-associated HIV DNA, integration sites, and clones in PBMCs from the donors put on ART shortly after infection 
(groups 1 and 2)A
Group Stage (PID) HIV DNA per 106 cells 
(fold decline from pre-
ART)
Cells (×106) used for ISA Unique integration 
sites
Number of clones 
detected
Number identical to 
pre-ART clones
1a
FIII (CH 83-1) 170 (294) 1.5 47 2 0
FIII (CH 84-4) 4 (425) 1.5 8A 2A 0
FIV PITT-001 ND 1.5 107A 6A 0
Average per 106 cells 87 (360) 36 2.2
SD 120 33 1.5
1b
FIV/V (62-1) 380 (47) 1.5 222A 19A 5
FV (68-5) 120 (47) 1.5 25 1 0
FV (91-4) 34 (141) 1.5 132A 2A 0
FV (98-6) 35 (54) 1.5 140A 4A 2
Average per 106 cells 140 (72) 87 4.3 1.5
SD 160 54 5.8
2
FV (IDFU-192) 270 (63) 3 509 23 0
FV (IDFU-194) 190 (8) 3 39 1 0
FV/VI (AVBIO2-14) 65 (66) 1 189 21 0
FV/VI (AVBIO2-23) 330 (63) 0.8 124 7 0
FVI (AVBIO2-04) 30 (70) 3 147 16 0
Average per 106 cells 180 (54) 93 6.3 0
SD 130 79 8.3
AIncludes data from 1 or 2 intermediate on-ART time points. A list of the clones detected at the intermediate time points is given in Supplemental Table 2. 
A complete list of the integration sites from all the time points is available on the RID Database (https://rid.ncifcrf.gov). F, Fiebig; PID, patient identifier; 
ISA, integration site analysis.
noted earlier, the viral DNA levels were much lower in the on-ART samples, reflecting the loss of  most of  
the recently infected cells, and, as a consequence, we obtained fewer integration sites. Despite having fewer 
integration sites from the on-ART than the pre-ART samples, the fraction of  the integration sites that were 
shown to be in clones was significantly higher in the on-ART than in the pre-ART samples (P < 0.001; Table 
5), independent of  the Fiebig stage at which ART was initiated. Notably, the fraction of  integration sites that 
were shown to be in clones (ca. 0.1) was not significantly different for the on-ART samples from the Fiebig 
III individuals compared to the samples from all the later groups (Figure 1C, orange squares; P > 0.6). This 
result is consistent with the conclusion that, although the time between infection and acquisition of  the pre-
ART sample in the Fiebig III–IV individuals was apparently too short for the clones to grow large enough 
to be unambiguously detected, small clones were present and continued to grow after the initiation of  ART 
blocked viral replication. This idea is strongly supported by the fact that a number of  the clones that were 
detected in the pre-ART samples taken from the Fiebig IV/V–V individuals were also detected in samples 
taken at later time points (Table 2, last column, and Supplemental Table 1). This result shows that PBMCs 
infected in the first few weeks of  infection can form clones rapidly and that some of  the clones that arise 
early can persist for years.
Broadly speaking, the group 2 pre-ART samples had a lower level of  viral DNA and we did not recover 
as many integration sites from the group 2 pre-ART samples as we did from the group 1 pre-ART samples 
(Table 2). However, probably because the numbers of  integration sites we recovered was small, the difference 
in the number of  recovered integration sites was not statistically significant (P > 0.2). We analyzed samples 
from 4 of  the group 2 individuals that were taken after they had been on suppressive ART for periods up 
to 17.8 years. Despite having relatively few integration sites from one of  the on-ART samples, we identified 
clones of  infected cells from the on-ART samples from all 5 of  the group 2 donors (Table 3). As was the 
case with the clonally expanded infected cells from group 1, these clones appear to have arisen from cells 
that were infected early and expanded until they became large enough that they were detected in on-ART 
samples collected years later. Unlike the infected clones in the Fiebig IV/V–V donors in group 1, none of  
the clones from the group 2 donors were detected in both the pre-ART and on-ART PBMCs, which likely 
reflects the small numbers of  integration sites obtained.
In contrast to the acutely infected individuals (groups 1 and 2) in whom some of  the clones of  
infected cells may have been expanding when the pre-ART samples were collected, in the individuals 
who had been infected for several years prior to ART initiation (group 3), most of  the clones of  infected 
cells were probably not still expanding rapidly. The fraction of  the integration sites in clones, relative 
to the total number of  integration sites recovered in the pre-ART samples (0.87%), was similar to the 
pre-ART samples from Fiebig IV/V–V (group 1b, 1.2%, P = 0.32) and somewhat greater than Fiebig 
V–VI (group 2, 0.07%, P = 0.014). Despite considerable patient-to-patient variation and the small num-
ber of  clones identified, this similarity suggests that a number of  the infected cells destined to expand 
Table 4. Cell-associated HIV DNA, integration sites, and clones in PBMCs from chronically infected patients
PID Pre-ART Samples Final On-ART Samples


























AVBIO2-21 1800 1.5 97 3 2 190 (9.5) 1.5 178A 11A 2
AVBIO2-08 3000 0.9 78 0 1 184 (16) 1.5  28 1 1
AVBIO2-18 5700 1.5 167 1 0 249 (23) 1.5 117B 16B 0
AVBIO1-102 810 1.5 46 0 0 311 (2.6) 1.5 28 1 0
AVBIO2-03 5700 1.5 66 0 0 926 (6.2) 1.5 129 9 0
Average per 
106 cells
3402 66 0.6 0.5 372 (11) 1.5 64 5.1
SD 2237 32 1.1 0.7 310  44 4.4
AData previously published in Table S3 of Maldarelli et al. (25), patient 3.BData previously published in Table S3 of Maldarelli et al. (25), patient 4. PID, 
patient identifier; ISA, integration site analysis.
into clones large enough to be detectable had already been infected, and the clones had already begun 
to expand, very soon after the initial infection. Moreover, the fraction of  cells that were detected as 
being in clones in the on-ART samples from the individuals who started ART during chronic infection 
(8%) was similar to the fraction in clones in the on-ART samples in the 2 groups of  participants who 
initiated ART much sooner (all around 6%) (P > 0.09; Table 5). These data strongly suggest that the 
large difference in the frequency at which clones were detected in the samples taken before ART and on 
ART is due to the presence in the pre-ART samples of  large numbers of  short-lived, recently infected 
cells. In pre-ART samples, the majority of  the proviruses are in recently infected cells, which, as was 
noted earlier, creates a background that makes it more difficult to detect clones using integration site 
analysis. However, we did see clonally expanded cells in the pre-ART samples from 2 of  the individuals 
who initiated treatment in chronic infection. All 3 of  the clones that were detected before ART were 
also detected in the on-ART sample from the same donor. This observation is similar to what was 
observed in group 1, where 7 of  the 11 clones identified in pre-ART samples from the Fiebig IV/V–V 
patients were also found in the on-ART samples (Supplemental Table 1). The similarity in the frequency 
at which clones were detected in the Fiebig IV/V–V samples and in the samples taken at later stages 
implies that the distribution in the sizes of  the infected clones has reached approximately its final value 
in the first few months after infection.
Discussion
We and others have proposed that clonal expansion of HIV-infected cells plays an important role in the gener-
ation and maintenance of the reservoir that has made it impossible to cure HIV infection with ART alone. Nor 
will it be possible to eliminate the reservoir with any combination of antiretrovirals that suppress HIV replication 
by blocking new cycles of replication because this type of therapy has no effect on cells that are already infected 
(25, 26). In some cases, clonally expanded cells can produce infectious virus and release it into the blood at levels 
that can readily be detected (28, 31). The goal of the present study was to better understand the formation and 
persistence of clones of infected cells after initial infection. We have obtained similar results in an SIV-macaque 
model of HIV persistence (40); i.e., clones of SIV-infected cells appear within a few weeks of infection, some of  
which persist and expand for at least a year of suppressive ART. The similarity of these results and of the distri-
bution of HIV integration sites in human cells and SIV integration sites in both macaque and human cells shows 
that the SIV/macaque model can be used in further studies of HIV clonal expansion and persistence.
We analyzed the integration sites in PBMC DNA in 2 groups of  HIV-infected donors who initiated 
ART early after infection, ranging from Fiebig III–VI (ca. 20 days to several months) and compared the 
results with a group of  donors who had been infected for years prior to initiating ART. Our results are 
summarized for the participants treated at different stages in Table 5, and graphically in Figure 1. We show 
Table 5. Summary of all results































FIII–IV (3) ~20–30 22,000 ± 
25,000
289 ± 209 0.67 (0.23)A ±  
0.51
0 (<.058)B,C 87 (360) ± 120 36 ± 33 2.2 (6.2)C,D ± 1.5
FIV/V–V (4) ~30–100 7,600 ± 7,100 124 ± 42 1.5 (1.2)A,E ± 1.2 0.89 (0.72)B,F ± 
0.90
140 (72) ± 164 87 ± 54 5.5 (6.4)C,D ± 7.2




180 (54) ± 130 94 ± 78 6.2 (6.6)C,D ± 8.3




370 (11) ± 310 64 ± 32 5.1 (7.9)C,D ± 4.4
AP = 7.6 × 10–4 (Fisher’s exact test). BP = 2.0 × 10–4 (Fisher’s exact test). CP < 0.001 (binomial test, all comparisons). DP > 0.05 (Fisher’s exact test, all 
comparisons). EP > 0.1 (Fisher’s exact test, all comparisons). FP > 0.9 (Fisher’s exact test). GP = 0.014 (Fisher’s exact test). P > 0.09 (Fisher’s exact test), for 
comparisons of groups 1a, 1b, and 2 with group 3.
that clones of  infected cells can arise soon after HIV is acquired, and that, in a period of  about 4 weeks, can 
grow large enough for us to detect (estimated to be >1 × 105 cells). Some of  the clones that were detected in 
the first few weeks persisted for years in infected individuals (Supplemental Table 1).
To test whether there was significant ongoing viral replication during ART treatment, which would 
mean that some of  the integrated DNA in the on-ART samples could have been from newly infected 
cells, we asked if  there was any evidence of  viral evolution in a subset of  the donors in group 1. We 
used SGS to compare the pre-ART viral DNA sequences in PBMCs from 5 of  the group 1 participants 
who did not have any treatment interruptions (Fiebig III to V) with samples taken after approximately 
3–4 years of  suppressive ART (Figure 2). The extremely low diversity of  the viral DNA implied that all 
donors were initially infected with a single founder virus, which is the case in about 80% of  infections 
(4, 37). Further, there was no measurable divergence in the viral sequences during the period of  sup-
pression, consistent with our previous findings for children treated early in life (7), which shows there 
was very little or no viral replication on ART. Thus, the reservoir is generated and sustained by the 
clonal expansion and long-term survival of  cells that were infected before ART was initiated. Because 
ART was initiated early in these donors, some or all of  the cells that gave rise to the clones must have 
Figure 1. Summary of the results for all of the donors in Tables 2–5. (A and B) The plots show the individual pre-ART 
(blue circles) and on-ART (orange squares) data, which were obtained from donors who were diagnosed and put on ART 
in Fiebig stage III–IV (group 1a), Fiebig stage IV/V–V (group 1b), Fiebig stages V/VI–VI (group 2), or were chronically infect-
ed at the time treatment was initiated. (A) Total HIV DNA per million PBMCs. (B) Integration sites recovered per million 
PBMCs. (C) Frequency of all integration sites with more than 1 breakpoint (green circles) or in confirmed clones (purple 
circles). Orange squares in C indicate frequency of clones in the on-ART PBMC samples from the same donors. Open 
symbols denote samples with no integrations in clones or with more than 1 breakpoint, plotted at the limit of detection 
(1/number of sites in all samples). Horizontal bars show the ratio for each group as a whole. The open purple bar in the 
Fiebig III–IV group, which had no confirmed clones, indicates the limit of detection of clones for the group as a whole.
been infected either during, or very shortly after, the eclipse period following viral transmission. This 
conclusion is strongly supported by the observation that some of  the clones of  infected cells detected in 
the pre-ART samples were also detected after several years of  suppressive ART (Supplemental Table 1).
As can be seen in Figure 1A, there was a significant reduction in the amount of  total viral DNA in 
the on-ART samples compared to the pre-ART samples. The viral load dropped about 100-fold in the 
participants who initiated therapy during Fiebig III–IV, about 10-fold in the participants who initiated 
therapy during chronic infection, and by intermediate amounts in the Fiebig IV/V–VI donors. These data 
are consistent with prior reports based on a larger number of  samples (17, 35, 36), and reflect a reduction in 
the proportion of  the total viral DNA present in recently infected, short-lived cells compared with the viral 
DNA in long-lived cells, which are generated less frequently and accumulate more slowly. As expected, 
there was a correlation between the amount of  viral DNA present in the various samples and our ability to 
recover integration sites (Supplemental Figure 1). As shown in Figure 1C, we were not able to unambigu-
ously identify expanded clones of  infected cells (<0.2% of  total proviruses) in pre-ART samples taken from 
participants initially tested at Fiebig stage III or IV, but the fraction of  infected cells that was confirmed to 
be in clones was approximately the same (about 1% of  the total integration sites) in the pre-ART samples 
taken at all stages after Fiebig IV. However, in all of  the samples taken after a year or more of  suppressive 
ART, including the samples from individuals who initiated therapy in Fiebig III–IV, approximately the 
same fraction of  infected cells was found in clones (ca. 5%–10%). This fraction is lower than what we 
reported in Maldarelli et al. (25) (about 40%) because, generally speaking, we analyzed fewer integration 
sites from the on-ART samples we report here, and our ability to detect clones depends on the number of  
integration sites we obtain from a sample. This result implies that cells that were infected at any time, rel-
ative to the initial infection of  the host, have approximately the same potential for clonal expansion. The 
only difference is that, before early Fiebig V (approximately 4 weeks), infected clones do not have enough 
time to expand to a size large enough for us to determine unambiguously that they have clonally expanded. 
Figure 2. Neighbor-joining trees of P6-PR-RT single-genome sequences. Single proviral sequences were obtained from pre-ART and on-ART PBMCs 
collected from donors who were fully suppressed for the duration of the study (no blips and no treatment interruptions). Neighbor-joining trees 
were inferred using MEGA, with the consensus subtype B HIV sequence as an outgroup. Pre-ART proviral sequences are shown in open triangles and 
on-ART proviral sequences in closed triangles. Sequences with long branches due to G to A hypermutations, which are formed at the time of infection 
and found in all patients, are not shown, but the numbers of hypermutant sequences found at both time points are shown above each tree. PID, 
patient identifier; APD, average pairwise distance.
It would take approximately 16–17 cell divisions for a clone to grow to a size we can expect to detect (ca. 1 
× 105 cells). The doubling time of  activated CD4+ T cells in HIV-infected humans is not known. If  the dou-
bling time is approximately 1 day, it takes a little over 2 weeks for an infected cell to grow to a size we could 
detect. If  the doubling time is 11 hours, as calculated in mice infected with lymphocytic choriomeningitis 
virus (LCMV) (41), then clones could grow to visible size in a little over 1 week. This result is consistent 
with data that show that the reservoir is formed very early in both HIV-infected humans and SIV-infected 
macaques (17, 18, 42).
In an untreated individual, integrated viral DNA can be either in recently infected cells that express viral 
proteins and are destined to die within 1 or 2 days, or in cells that carry defective or latent proviruses that 
may not express viral proteins. Some of  those cells can survive and divide for many years. As our results 
show, the relative numbers of  the different types of  infected cells change with time, both off  and on ART, as 
the numbers of  new productively infected cells increase or decline. Cells with latent and defective proviruses 
accumulate by division as well as by new infection. In samples taken from untreated individuals, much of  the 
viral DNA is in newly infected cells, creating a background that makes it more difficult to use integration site 
analysis to detect clonally expanded infected cells. Furthermore, although some of  the proviruses detected 
by our assay with 2 breakpoints may be from clones of  infected cells, they may also be from single cells that 
have replicated their DNA but not yet divided. HIV encodes a protein, Vpr, that specifically causes cell cycle 
arrest in the G2 stage. In cells infected in culture, Vpr leads to the accumulation of  cells with 4n DNA content 
(22). Although the extent of  the G2 block and how long any G2-blocked cells survive in infected individuals 
are unclear, there is a real possibility that there could be newly infected cells that have replicated their DNA, 
including a newly integrated provirus, that will not go on to make clones in untreated individuals.
In contrast, if  there are cells that have replicated their viral DNA in an individual who has been on 
ART for years, those cells are almost certainly members of  a clone. As a consequence, in on-ART samples, 
if  we recover the same end of  a provirus 2 (or more) times, with different lengths of  appended host DNA 
(2 or more different breakpoints), we can safely conclude that the integration site is from a clone. For that 
reason, in pre-ART samples, we only counted integration sites as coming from a clone if  we isolated the 
integration site 3 or more times, or if  an integration site that was found in a pre-ART sample was also 
present in at least one other sample taken from the same individual. Thus, the integration site data, and 
the clone counts, are not strictly comparable in samples taken from pre-ART and on-ART donors, and for 
that reason the pre-ART data and the on-ART data are presented in different tables and the proportions of  
integration sites with more than 1 breakpoint are shown by open bars in Figure 1C.
Using these strict rules, in pre-ART samples taken from donors at FIV/V or later, we were able to 
identify integration sites in clonally expanded cells. In contrast, none of  the integration sites with 2 
breakpoints in the samples taken at earlier Fiebig stages could be confirmed as being in clones. Given 
the small size of  the samples assayed (ca. 1–5 million cells) relative to the total estimated number of  
CD4+ T cells (ca. 5 × 1012) in the whole body, we can expect to reliably detect infected clones only 
after they have grown larger than 1 × 105 cells (see Methods). Using what is the shortest estimated 
doubling time for CD4+ T cells in viral infection (about 11 hours), based on analyses of  mice infected 
with LCMV (41), it would take an infected cell about 1 week to reach this size. Although additional 
analysis, involving more donors and samples taken at different time points, will be required to deter-
mine if  there are rare, large clones of  infected cells that arise earlier, we do know that there are some 
large clones present about 1 month after the initial infection, and that some of  the clones that arise 
early can persist for years.
These results have important implications for strategies designed to control or eliminate the reservoir 
of  infectious proviruses in a way that would allow infected individuals to go off  ART. First, clonal expan-
sion of  infected cells explains why continuous and effective ART is not sufficient to cure an infected 
individual, and why modifying ART, either by adding additional antiviral drugs, or substituting more 
potent drugs, does not reduce or eliminate the reservoir (29, 30, 43). Additionally, clonal expansion of  
infected cells also explains why the HIV DNA levels, persistent low-level viremia, and, in all probability, 
the size of  the reservoir, decays only very slowly after the first few years of  successful ART (20, 21). 
Even if, over time, some infected cells die (including cells in clones), the replication of  infected cells, in 
particular those that carry infectious proviruses, is sufficient to maintain the level of  HIV DNA, and the 
reservoir. Thus, it is clonal expansion, which can be driven by antigen recognition and/or homeostatic 
stimulation, that causes HIV-infected cells to persist, including cells carrying intact infectious proviruses.
Second, eliminating the reservoir is not a problem of  blocking viral replication, but is rather a 
problem of  eliminating all the infected cells that carry infectious proviruses, at least some of  which 
have clonally expanded. It is likely that the forces which drove the clonal expansion in the first place 
will still be present following the administration of  a curative therapy, such as “kick and kill” (44). 
Even if  a strategy is found that activates the expression of  all of  the infectious proviruses in the cells 
of  a particular clone, leading to the elimination of  that clone, it is not clear that such a strategy would 
be able to successfully activate all of  the infectious proviruses that are in all of  the different clones of  
expanded cells. The observation that the predominant virus that arises following ex vivo activation of  
latently infected cells is often genetically distinct from that which rebounds following ART interrup-
tion (45) implies that we still have much to learn about the regulation of  expression in vivo before such 
a strategy can be put into place.
Finally, our data point to the magnitude of  the problem of  eliminating all the intact, infectious 
proviruses that comprise the HIV reservoir. On average, infected individuals on suppressive ART have 
been reported to have about 1 provirus per 2,000 PBMCs (35). Our results, based on both the viral DNA 
level and the integration site data, are similar, corresponding to about 10 million proviruses in the blood 
and about half  a billion proviruses in the whole body. Although most of  these proviruses are defective, 
current estimates suggest that, in those on long-term ART, the intact, infectious proviruses represent a 
few percent of  the total (9). This calculation suggests that an infected individual whose HIV replication 
is fully suppressed contains approximately 10 million cells that carry intact infectious proviruses, most 
likely distributed over hundreds to thousands of  clones. The fact that we have previously identified a 
single clone of  about 10 million cells that carries an infectious provirus (28) suggests that, in at least 
some individuals, the reservoir could be larger. Every cell that carries a fully intact provirus has the 
potential to release infectious virus that could rekindle the infection. Although it has been possible to 
eliminate large masses of  tumor tissue with immunotherapy, the tumor cells that respond to immuno-
therapy express antigens that make it possible to target them (44). If, as appears to be the case, most of  
the HIV-infected cells that carry intact proviruses do not express viral RNA or proteins, eliminating the 
HIV-infected cells that carry fully intact proviruses will require a strategy that activates the expression 
of  the proviruses in all, or almost all, of  the cells that carry latent infectious proviruses or an alternative 
strategy that prevents any expressed virus from rekindling a systemic infection.
Methods
Donor samples. Cryopreserved PBMCs were obtained from several sources: individuals enrolled in the 
UNC-Duke Acute HIV Treatment Cohort and CHAVI-001 at University of  North Carolina, Chapel Hill; 
individuals enrolled in the Acute HIV Infection study at the University of  Pittsburgh (protocol 15120105); 
and individuals participating in AVBIO1 and AVBIO2, studies of  the effects of  ART in HIV-infected 
adults (NIH protocol 97-I-0082, 08-I-0221), as well as IDFU, a natural history study of  HIV-infected 
individuals undergoing ART (NIH protocol 95-I-0072).All participants gave informed written consent to 
allow samples to be used for additional research. All studies were approved by the respective Institutional 
Review Boards (University of  North Carolina: IRB and the Office of  Human Research Ethics, University 
of  North Carolina at Chapel Hill; FWA 00004801, expiration 10/15/2023. NIH: National Institute of  
Allergy and Infectious Diseases IRB located at the NIH Clinical Center, Bethesda, Maryland, USA; FWA 
00005897, expiration 7/16/2023. University of  Pittsburgh: IRB at the University of  Pittsburgh Common-
wealth System of  Higher Education; FWA00006790, expiration 7/1/2020).
Fiebig staging. The Fiebig stage of  the donors was established using standard methods for plasma HIV 
RNA detection, soluble plasma p24 detection, screening using EIA for HIV antibodies (third or fourth 
generation tests), and Western blot as described by Fiebig et al. (34).
Quantification of  plasma HIV-1 RNA. Plasma HIV-1 RNA measurements were performed using the 
FDA-approved Abbott HIV Real-time Assay on the M2000 instrument (LOD 40 copies/mL plasma), version 
2 Quantiplex HIV RNA bDNA version 2 (LOD 500 copy/mL plasma), version 3 Quantiplex HIV RNA 
bDNA (LOD 50 copies/mL plasma), or Roche HIV Monitor ultrasensitive version 1.5 (LOD 50 copies/mL).
Measurements of  HIV DNA. Total HIV-1 DNA in PBMCs was quantified as previously reported (46). 
Briefly, total nucleic acid was isolated from 2.5 million PBMCs using proteinase K/guanidinium HCl/
guanidinium thiocyanate lysis and isopropanol precipitation. The amplification target is in the 3′ end of  
pol. The LOD for HIV-1 DNA was 1 copy per reaction, as determined by limiting-dilution analysis of  
DNA standards. Seven hundred nanograms of  DNA was used for each qPCR reaction. The number of  
cell equivalents was estimated by qPCR amplification of  CCR5 according to a published protocol (47) and 
was used to normalize the levels of  HIV-1 DNA.
Single-genome sequencing. SGS was performed on the P6-PR-RT region of the genome as previously described 
(4, 48). PBMC DNA was extracted using the methods described in Van Zyl et al. (7). Clustal W alignments and 
neighbor-joining phylogenetic analyses were performed using MEGA 6 (https://www.megasoftware.net/).
Integration site assay. Integration site analysis was performed as previously described (25). Briefly, 
DNA was isolated from PBMCs of  infected donors. Genomic DNA was fragmented by random shearing 
into 300- to 500-bp fragments. Linker-mediated nested PCR was performed to amplify the human and 
linked HIV sequences from both the 5′ and 3′ LTRs. Paired-end sequencing was carried out using the 
MiSeq 2 × 150 bp paired-end kit (Illumina). The sequences of  the host-virus junctions and the host DNA 
breakpoints were determined. The host DNA sequences were then mapped to human genome (hg19) 
using BLAT. A stringent filter for mispriming and other possible artifacts was included in the pipeline 
used to check quality of  recovered integration sites.
Identifying clones of  infected cells in pre-ART samples. Most of  the previous analysis of  the clonal expansion 
of  HIV-infected cells involved the analysis of  samples taken from individuals who had been on successful 
ART for years. In samples taken from donors who were on long-term ART, when we obtained exactly the 
same integration site twice (with different breakpoints), it was taken as evidence that the cells had clonally 
expanded. This conclusion followed from the absence, in the donors we were studying (who were on suc-
cessful ART), of  newly infected cells. It is formally possible that there were, in some of  the samples from 
individuals on ART, single infected cells in S, G2, or M that contained 2 copies of  a provirus that was present 
only once when the cells were in G1. However, if  there are any infected cells that are dividing after years of  
successful ART, it is quite likely that these cells are part of  a clone. The situation is different in an untreated 
HIV-infected human, in which there are large numbers of  newly infected cells that will live only for 1 or 2 
days. HIV preferentially infects activated T cells. It is likely that some of  the newly infected cells will repli-
cate their DNA but die before they can divide, much less form a clone. As such, finding the same integration 
site twice in a single sample from an untreated donor is not sufficient to determine that the infected cell was 
part of  an expanded clone. We use 2 criteria to identify clones in samples taken from untreated humans: (a) 
the integration site was isolated 3 or more times in a single integration site assay (with different breakpoints); 
and (b) the integration site was seen in 2 (or more) independent assays, either done with cells taken at the 
same time, or at different times, either before, or after, the initiation of  ART. For samples taken from donors 
on ART, the isolation of  the same integration site twice is still considered to be evidence that there is an 
infected clone of  cells in the sample.
Calculation of  the likelihood of  detecting a clone by integration site analysis relative to the number of  cells in 
the clone in the patient. On average, an HIV-infected individual on therapy has about 1 provirus per 1,000 
CD4+ T cells. Given a total of  about 1 × 1010 CD4+ T cells in blood, and nearly 1 × 1012 cells in the whole 
body, this implies that there are roughly 1 × 109 infected cells if  the CD4+ T cell count is near normal, 
and substantially less if  the count is lower. Some of  the infected cells will have clonally expanded and the 
cells in each infected clone will have a provirus with an identical integration site. We want to know the 
probability, if  we sample the population N times, that we can detect a clone of  a particular size. We per-
formed a calculation based on the suppositions that we obtained a total of  100 integration sites, 500 sites, 
1,000 sites, etc., from an infected individual. Given a population of  1 × 108 total cells, if  we start with the 
case in which we obtained 1,000 integration sites, and if  we have a clone that comprises 1 × 105 cells, the 
expected number of  times we would obtain the integration site for the clone would be 1. To detect a clone 
in a patient on ART, we need to see the integration site for the clone of  interest at least twice. We can use 
the Poisson distribution to get the probability of  obtaining the same integration site 2 (or more) times. The 
probability is the sum of  the Poisson values (based on an average of  1) for which the number of  positives 
was greater than or equal to 2, or, more simply, 1 minus the sum of  the Poisson expectations for 0 and 1 
(Supplemental Table 3).
Statistics. In the comparisons between different groups of  individuals of  the number of  identified clones 
relative to the number of  observed integration sites, the data can be presented in a 2 × 2 contingency table. 
The rows would represent the number of  clones and insertion sites and the columns the different groups. 
As such, the significance of  the relative difference in the fraction of  clones for the 2 groups was determined 
using Fisher’s exact test. Although the original Fisher’s test was a 1-tail test (49), current implementations 
(such as in R) have converted this to a 2-tailed test based on the probability that the odds ratio is 1 (50). 
Therefore, all P values presented here are 2-tailed values, with one exception. When the difference between 
the fractions of  clones before ART and on ART were compared for a single group, it was clear that the 
fraction was higher on ART. Therefore, the significance of  this difference was determined using a 1-tailed 
binomial test. All statistical analyses were preformed either on an isolated single group or pair of  groups. 
Because each group, or each pair of  groups, was examined independently, no correction for multiple 
comparisons was used. We determined whether each specific difference was significant, not whether any 
difference was significant.
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